Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) released its quarterly earnings results on Tuesday. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09, FiscalAI reports. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $207.12 million. During the same period in the previous year, the company posted $0.11 EPS. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% on a year-over-year basis.

Here are the key takeaways from Kiniksa Pharmaceuticals International’s conference call:

• ARCALYST delivered $214.3 million in Q1 net revenue (+56% YoY) and the company raised full‑year 2026 revenue guidance to $930M–$945M (from $900M–$920M).
• Commercial momentum accelerated with ~400 new prescribers in Q1 (the largest quarterly gain since launch) bringing total prescribers to >4,550, and Kiniksa launched a targeted, AI‑driven DTC campaign (“Heart’s Home”) intended to cost‑effectively drive patient‑initiated prescribing.
• The company adjusted its copay assistance program to reduce average copay payouts, which helped gross‑to‑net versus prior year, but Q1 gross‑to‑net was higher than Q4 and remains exposed to seasonal payer dynamics and co‑pay resets.
• Pipeline progress — the integrated KPL‑387 phase II/III is on track with dose‑focusing data expected in H2 2026 and phase III planned to start by year‑end 2026, and KPL‑1161 is targeted to enter phase I by year‑end.
• Financial strength — Q1 net income rose to $22.6 million (vs. $8.5M a year ago), ARCALYST collaboration profit was up 73% to $151.2 million, and cash totaled $468.1 million, with management expecting to remain cash‑flow positive on an annual basis.

Kiniksa Pharmaceuticals International Stock Up 0.8%

Shares of KNSA traded up $0.41 during midday trading on Thursday, hitting $53.40. The company had a trading volume of 335,988 shares, compared to its average volume of 700,969. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of 72.14 and a beta of 0.06. The company’s 50 day moving average price is $46.26 and its 200 day moving average price is $43.04. Kiniksa Pharmaceuticals International has a 52 week low of $24.85 and a 52 week high of $54.31.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Friday, April 17th. Canaccord Genuity Group raised their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Sunday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.86.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 6,625 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares of the company’s stock, valued at $1,280,146.42. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the sale, the chief financial officer owned 12,086 shares in the company, valued at $523,082.08. The trade was a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 74,578 shares of company stock valued at $3,489,072. 53.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds have recently added to or reduced their stakes in KNSA. Rubric Capital Management LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after purchasing an additional 90,194 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after acquiring an additional 332,846 shares during the period. Qube Research & Technologies Ltd boosted its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after acquiring an additional 653,236 shares during the period. Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 51.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 829,417 shares of the company’s stock worth $34,213,000 after purchasing an additional 282,907 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat — Kiniksa reported $0.27 EPS vs. consensus $0.18 and revenue of $214.3M (≈+55.5% YoY), driven by ARCALYST product growth; this improves near‑term earnings visibility. Press Release
• Positive Sentiment: Raised guidance — FY‑2026 revenue outlook lifted to $930M–$945M (above the Street), prompting model revisions and supporting valuation expansion. Guidance Release
• Positive Sentiment: Analyst momentum — multiple firms raised targets and reiterated buys (Jefferies to $71, Citigroup to $60, Canaccord to $64, Wedbush to $59, Wells Fargo to $57), increasing buy‑side interest and liquidity. Analyst Notes More
• Positive Sentiment: Product & pipeline tailwinds — ARCALYST net product revenue strength and management’s raised ARCALYST outlook support revenue durability; upcoming KPL‑387 Phase 2 readout (2H‑2026) and a planned Phase 3 could be meaningful catalysts. Read More.
• Neutral Sentiment: Investor materials available — the Q1 earnings slide deck and full call transcript are posted for diligence; they contain detail on channel dynamics, margins and guidance assumptions. Read More. Read More.
• Negative Sentiment: Insider selling — director Barry D. Quart sold 13,099 shares at ~$50.10 under a pre‑arranged Rule 10b5‑1 plan, reducing his stake ~51%; while planned, insider sales can create short‑term pressure on sentiment. Read More. Read More.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.